Low‐dose diosbulbin‐B (DB) could inhibit properties of cancer stem cells and induce PD‐L1 depletion to activate NLRP3‐dependent pyroptosis, which effetely sensitize cisplatin‐resistant GC cells. The gene discussed is NLRP3; the disease is cancer.